Press Releases & Articles

•TTC Oncology LLC Signs a Collaboration Agreement with Lantern Pharma | Newswire

•TTC Oncology to Present at Biotech Showcase™ Digital 2021 | Business Wire

•TTC-352 for Breast Cancers Resistant to Hormone Therapy Seen as Safe in Phase 1 Trial (breastcancer-news.com)

•New breast cancer drug is safe and effective, can halt disease progression (news-medical.net)

•Phase 1 human trials suggest UIC-developed breast cancer drug is safe, effective | EurekAlert! Science News

•So far, First time’s a charm for Tonetti’s initial clinical trial – University of Illinois Cancer Center (uillinois.edu)

•UIC breast cancer drug in first human clinical trial | UIC Today

Publications and Presentations at Scientific Meetings

•“Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer” Abderrahman B, et al. Mol Cancer Ther. 2021. PMID: 33177154 (pubmed)

•Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy – PubMed (nih.gov)

•Abstract CT051: Phase I study of TTC-352 in patients with estrogen receptor-positive metastatic breast cancer | Cancer Research (aacrjournals.org)

•Study TTC-352-101: Phase 1 study of TTC-352 in patients with metastatic breast cancer (BC) progressing on endocrine therapy. | Journal of Clinical Oncology (ascopubs.org)

First time’s a charm for Tonetti’s intiial clinical trial

Through this exciting new series, SparkTalks, UIC is igniting the thoughts and solutions of influential UIC changemakers

TTC-352, A selective estrogen mimic, causes complete tumor regression

TTC-352 Safe for Patients Resistant to Hormone Therapy, Phase 1 Trial finds

We believe our AI powered collaboration with TTC Oncology will accelerate the clinical development of TTC 352 for patients with metastatic ER+ breast cancer and will also identify new potential patient populations that can benefit from TTC-352 treatment: Panna Sharma, Lantern Pharma CEO and President

New breast cancer drug is safe and effective, can halt disease progression

TTC-352 is a safe and tolerable alternative to chemotherapy-therefore, without the side effects of chemotherapy

Based on these encouraging results, TTC Oncology are planning to be commercially indicated as a second-line therapy of ER+ breast cancer